(2S)-2-methyl-1-(o-tolyl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (2S)-2-methyl-1-(o-tolyl)piperazine
• 英文别名: (2S)-2-methyl-1-(2-methylphenyl)piperazine
• 化学式: C₁₂H₁₈N₂
• 分子量: 190.288
• InChiKey: BOGVRSLRVPJJQG-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES
  申请人：UCB Biopharma SPRL

  公开号：EP3527209A1

  公开（公告）日：2019-08-21

  The invention relates to 6,5 heterobicyclic ring derivatives, processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as SLE and geographic atrophy.

  该发明涉及6,5杂环环衍生物，其制备方法，含有它们的药物组合物以及它们用于治疗由STING激活驱动的炎症性疾病，如SLE和地理性萎缩症。
• Pharmaceutical 6,5 Heterobicyclic Ring Derivatives
  申请人：UCB Biopharma SRL

  公开号：US20200399268A1

  公开（公告）日：2020-12-24

  The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.
• [EN] PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES<br/>[FR] DÉRIVÉS CYCLIQUES 6,5 HÉTÉROBICYCLIQUES PHARMACEUTIQUES
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2019158731A1

  公开（公告）日：2019-08-22

  The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.